Fidelity-Backed City Therapeutics Seeks $184.7 Million in US IPO
City Therapeutics Inc., an early-stage developer of RNAi-based drugs, is seeking to raise as much as $184.7 million in a US initial public offering.
By Angel Adegbesan ยท Bloomberg
City Therapeutics Inc., an early-stage developer of RNAi-based drugs, is seeking to raise as much as $184.7 million in a US initial public offering.